Stiripentol fails to lower plasma oxalate in a dialysis-dependent PH1 patient
Open Access
- 1 September 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Pediatric Nephrology
- Vol. 35 (9), 1787-1789
- https://doi.org/10.1007/s00467-020-04585-5
Abstract
Background Primary hyperoxaluria type 1 (PH1) is a multisystemic metabolic disorder caused by an excessive production of oxalate by the liver. The majority of patients presenting in early infancy have end-stage renal disease (ESRD). While awaiting the results of sRNAi trials, the current standard treatment is combined liver-kidney transplantation. Recently, Stiripentol has been reported as a promising drug in the treatment of primary hyperoxaluria by reducing urinary oxalate (U-Ox). Stiripentol is an anti-convulsive drug used in the treatment of children suffering from Dravet syndrome. It causes blockage of the last step in oxalate production by inhibition of hepatic lactate dehydrogenase 5 (LDH5). Case We administered Stiripentol as compassionate use in an anuric infant with dialysis-dependent PH1 over a period of 4 months. Although achieving plasma concentrations of Stiripentol that were recently reported to lower U-Ox excretion, we did not observe significant reduction to plasma oxalate concentrations (P-Ox). Conclusion We conclude that Stiripentol may not be useful to reduce P-Ox in PH patients with advanced chronic kidney disease (CKD), but larger studies are needed to confirm this finding.Funding Information
- Charité
This publication has 10 references indexed in Scilit:
- Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activityBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoningJCI Insight, 2019
- Combined liver-kidney transplantation for primary hyperoxaluria type I in children: Single Center ExperiencePediatric Transplantation, 2018
- Novel therapeutic approaches in primary hyperoxaluriaEmerging Drugs, 2018
- Reference ranges for antiepileptic drugs revisited: a practical approach to establish national guidelinesDrug Design, Development and Therapy, 2018
- Combined Liver–Kidney Transplantation for Primary Hyperoxaluria Type 2: A Case ReportAmerican Journal of Transplantation, 2017
- Impact of Regular or Extended Hemodialysis and Hemodialfiltration on Plasma Oxalate Concentrations in Patients With End-Stage Renal DiseaseKidney International Reports, 2017
- NALP3-mediated inflammation is a principal cause of progressive renal failure in oxalate nephropathyKidney International, 2013
- Primary HyperoxaluriaThe New England Journal of Medicine, 2013
- Hyperoxaluria and systemic oxalosis: an update on current therapy and future directionsExpert Opinion on Investigational Drugs, 2012